The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer.

doi:10.1158/1078-0432.CCR-20-1566

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2021

Jacob Saya, Davis Andrew A, Gerratana Lorenzo, Velimirovic Marko, Shah Ami N, Wehbe Firas, Katam Neelima, Zhang Qiang, Flaum Lisa, Siziopikou Kalliopi P, Platanias Leonidas C, Gradishar William J, Behdad Amir, Bardia Aditya, Cristofanilli Massimo

Abstract excerpt

PURPOSE: Circulating tumor DNA (ctDNA) is a promising tool for noninvasive longitudinal monitoring of genomic alterations. We analyzed serial ctDNA to characterize genomic evolution in progressive metastatic breast cancer. EXPERIMENTAL DESIGN: This was a retrospective cohort between 2015 and 2019 obtained under an Institutional Review Board-approved protocol at Northwestern University (Chicago, IL). ctDNA samples...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Breast Neoplasms

Share to Circulating Tumor DNA

Share to Drug Resistance, Neoplasm

Share to Follow-Up Studies

Share to High-Throughput Nucleotide Sequencing

Share to Prognosis

Source

Open in PubMed

Identifiers

PMID: 33323406
DOI: 10.1158/1078-0432.CCR-20-1566

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer.PMID 33323406Read ↗

Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer.Semantic proximity Read ↗

Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.Semantic proximity Read ↗

Prognostic and monitoring value of circulating tumor DNA at multiple clinical time points in breast cancer.Semantic proximity Read ↗

ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.Semantic proximity Read ↗

Landscape of circulating tumour DNA in metastatic breast cancer.Semantic proximity Read ↗

Serial Circulating Tumor DNA Identification Associated with the Efficacy and Prognosis of Neoadjuvant Chemotherapy in Breast CancerSemantic proximity Read ↗

Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast CancerSemantic proximity Read ↗

Clinical applications of circulating tumor DNA in monitoring breast cancer drug resistance.Semantic proximity Read ↗

Genomic Landscape of Circulating-Tumor DNA in a Diverse Cohort of Metastatic Breast Cancer Patients.Semantic proximity Read ↗

Noninvasive MRD monitoring and profiling of clonal evolution by ctDNA in patients with advanced cancers treated within molecular tumor boardsSemantic proximity Read ↗

Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer.Semantic proximity Read ↗

Clinical application of circulating tumor DNA in breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.